SX Topping Cement

Manufacturer: Bondex
Product Category: Joint Compound
Years Produced: 1961–1977
Asbestos Type: Chrysotile
Legal Tier: Tier 2 – Litigated Product

Product Description

SX Topping Cement was a finishing-grade joint compound manufactured by Bondex during the period spanning 1961 through 1977. As a topping compound, this product was formulated for use in the final stages of drywall finishing work, designed to produce smooth, paintable surfaces by filling seams, covering tape, and feathering joints between gypsum wallboard panels. Topping compounds of this era were distinct from all-purpose or taping-grade compounds in that they were engineered for lighter, thinner applications and prized for their workability and fine texture upon drying.

Bondex was an established manufacturer of construction finishing products throughout the mid-twentieth century, producing a range of patching, bonding, and surface preparation materials for residential, commercial, and industrial construction markets. SX Topping Cement represented one of the company’s offerings within the joint compound category during the period when chrysotile asbestos was widely incorporated into such products as a functional additive.

The use of asbestos-containing joint compounds was common industry practice during the 1960s and 1970s, and regulatory frameworks permitting such formulations remained in place for much of this period. It was not until growing awareness of asbestos-related health hazards — and eventual regulatory action — that manufacturers began reformulating or discontinuing products containing asbestos fibers.

Asbestos Content

SX Topping Cement contained chrysotile asbestos as a component of its dry formulation. Chrysotile, also known as white asbestos, is a serpentine-type mineral fiber that was extensively used in building materials throughout the twentieth century due to its tensile strength, fire resistance, and binding properties. In joint compound formulations, chrysotile asbestos served to improve workability, reduce cracking during the drying process, and add cohesive strength to the finished product.

Litigation records document that SX Topping Cement was identified as an asbestos-containing product in legal proceedings, with plaintiffs alleging that the compound incorporated chrysotile fibers in concentrations sufficient to generate hazardous airborne dust under ordinary conditions of use. The chrysotile fibers present in topping compounds such as this product were bound within the wet or dry compound matrix but were released into the air when the material was mixed, applied, sanded, or otherwise disturbed.

Chrysotile asbestos, while sometimes characterized as the least potent of the asbestos fiber types, is nonetheless classified as a known human carcinogen by the International Agency for Research on Cancer (IARC) and has been causally linked to mesothelioma, asbestosis, lung cancer, and other serious diseases following occupational inhalation exposure.

How Workers Were Exposed

Workers exposed to SX Topping Cement during its period of production and use — 1961 through 1977 — encountered chrysotile asbestos fibers primarily through the inhalation of airborne dust generated during mixing, application, and surface finishing activities. Industrial workers generally involved in construction, building maintenance, and related trades were among those potentially exposed in environments where the product was used.

The exposure pathway most associated with serious fiber release was the dry sanding of cured joint compound. After a topping coat applied with SX Topping Cement dried on a wall or ceiling surface, workers using sandpaper or sanding blocks to smooth and feather the compound would generate fine airborne dust laden with chrysotile fibers. Unlike larger debris, these microscopic fibers could remain suspended in the air for extended periods and were readily inhaled deep into the lung tissue.

Additional exposure occurred during the dry mixing of the compound, when workers opened bags of powdered product and combined the contents with water. This process could release a concentrated burst of airborne dust before any liquid was added to bind the fibers. Plaintiffs alleged that these mixing conditions, conducted in enclosed or poorly ventilated interior spaces, produced acute short-duration exposures of significant intensity.

Workers sanding, scraping, or otherwise disturbing previously applied SX Topping Cement — for example, during renovation or demolition activities — also faced potential secondary exposure to fibers released from aged and friable compound surfaces.

Litigation records document that during the period this product was on the market, effective respiratory protection was not consistently provided to workers handling asbestos-containing joint compounds, and employers were not always informed by manufacturers of the fiber content or the associated health risks. Plaintiffs alleged that Bondex had access to scientific and medical literature documenting the hazards of chrysotile asbestos inhalation during the years the product was sold, and that adequate warnings were not furnished on product packaging or through other channels.

The latency period characteristic of asbestos-related diseases — which may span ten to fifty years between initial exposure and clinical diagnosis — means that individuals exposed to SX Topping Cement during the 1960s and 1970s may still be developing related conditions today.

Documented Trust Fund / Legal Options

No dedicated asbestos bankruptcy trust fund has been established specifically for claims arising from Bondex SX Topping Cement. Bondex does not currently maintain a trust fund mechanism through which former workers or their survivors may file administrative claims. As a result, individuals harmed by exposure to this product are not able to pursue compensation through a trust fund filing process.

Legal recourse for those injured by exposure to SX Topping Cement has proceeded through the civil litigation system. Litigation records document that claims involving Bondex asbestos-containing products, including joint compound formulations, have been filed in state and federal courts by plaintiffs alleging diagnoses of mesothelioma, asbestosis, lung cancer, and related conditions attributable to occupational asbestos inhalation.

Plaintiffs alleged in such proceedings that Bondex knew or should have known of the hazards associated with chrysotile asbestos and failed to warn workers of those risks, resulting in preventable exposures and subsequent disease. Claims of this nature have typically asserted theories of negligence, strict product liability, and failure to warn.

Individuals who were exposed to SX Topping Cement and have since received a diagnosis of an asbestos-related disease should consult a qualified asbestos litigation attorney to evaluate the merits and timing of potential claims. Statutes of limitations governing asbestos personal injury and wrongful death actions vary by jurisdiction and generally begin to run from the date of disease diagnosis or, in some states, from the date the claimant knew or reasonably should have known of the connection between their illness and asbestos exposure.

An attorney experienced in asbestos litigation can conduct a thorough occupational exposure history, identify all relevant defendant parties, and determine whether viable claims exist under the laws of the applicable jurisdiction.